Search alternatives:
point decrease » point increase (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
point decrease » point increase (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
-
221
-
222
-
223
-
224
-
225
CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line.
Published 2014“…Immortalized HBECs with (A) lenti-<i>KRas</i><sup>V12</sup>, (B) lenti-<i>KRas</i><sup>V12</sup> and sh<i>p53</i> knockdown, and (C) lenti-<i>KRas</i><sup>V12</sup>, sh<i>p53</i>, and <i>myc</i> overexpression. …”
-
226
-
227
-
228
Wnt5a expressing tumors demonstrate a decrease in markers of the basal tumor subtype.
Published 2014“…MMTV-Wnt1;MMTV-Wnt5a tumors demonstrated a significant decrease in K6-expressing cells as measured by T-test (* = p<0.05).…”
-
229
-
230
Mitochondrial dysfunction is driven by decreased mitochondrial dynamics.
Published 2014“…<p>(A) Sensitivity analysis averaged along the time course for the mitochondrial species in the model by varying the mitochondrial-related kinetic rate constant parameters. …”
-
231
-
232
-
233
Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation.
Published 2013“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
-
234
-
235
-
236
OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts.
Published 2019“…After 4 weeks, when the tumor size was approximately 100 mm<sup>3</sup> (T<sub>0</sub>) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”
-
237
-
238
-
239
-
240